ACM
FBRX icon

ACT Capital Management’s Forte Biosciences FBRX Stock Holding History

ACT Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-643
Closed -$541K – 117
2021
Q2 		$541K Buy
+643
New +$579K 0.28% 64

Other funds holding FBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

ACT Capital Management's FBRX Position: Q3 2021 in Review

ACT Capital Management sold out of Forte Biosciences (FBRX) in Q3 2021, closing a stake of 643 shares — an estimated $541K sold.

ACT Capital Management first reported a position in FBRX in Q2 2021 and held it in 1 quarter. The position peaked at $541K in Q2 2021. 57 funds tracked by Wall St. Rank hold FBRX as of Q3 2021.

  • ACT Capital Management reported no remaining Forte Biosciences position as of Q3 2021 after selling out during the quarter.
  • ACT Capital Management sold 643 Forte Biosciences shares in Q3 2021, an estimated $541K.
  • ACT Capital Management first reported a position in Forte Biosciences in Q2 2021 and held it in 1 quarter.
  • ACT Capital Management's Forte Biosciences position peaked at $541K in Q2 2021.
  • 57 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2021.

Based on ACT Capital Management's 13F filing for Q3 2021, filed 16 Nov 2021.